Stargardt Disease - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035

Stargardt Disease Market Outlook

Thelansis's "Stargardt Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Stargardt Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Stargardt Disease Overview

Stargardt disease (STGD1) is the most common form of inherited juvenile macular degeneration, primarily caused by autosomal recessive mutations in the ABCA4 gene. This defect disrupts the transport of vitamin A derivatives, leading to toxic accumulation of bisretinoid compounds (lipofuscin) within the retinal pigment epithelium (RPE).

The resulting metabolic dysfunction drives progressive macular atrophy and secondary photoreceptor degeneration, clinically manifesting as loss of central vision, impaired color perception, and difficulty with dark adaptation, typically presenting in childhood or adolescence.

Diagnosis is supported by advanced imaging modalities such as optical coherence tomography (OCT) and fundus autofluorescence (FAF), which reveal characteristic retinal flecks and macular thinning.

Currently, there are no approved disease-modifying therapies, and management is largely supportive. However, the therapeutic landscape is evolving rapidly, with investigational approaches including visual cycle modulators, gene therapies, and cell-based treatments aimed at reducing toxic metabolite accumulation and preserving retinal function.

Key Highlights

• The incident Stargardt disease population is relatively small but steadily increasing, from 582 cases in 2025 to 622 cases by 2035, reflecting gradual improvements in diagnosis and genetic screening.
• The prevalent population is estimated at 27,426 cases in 2025, increasing to 29,343 by 2035, highlighting the chronic and progressive nature of the disease.
• The treated patient population remains high (89% treatment rate), increasing from 24,409 patients in 2025 to 26,116 by 2035, largely driven by supportive care and emerging therapy access.
• A female predominance (62%) is observed compared to males (38%), consistent across the forecast period.
• Disease burden spans across age groups but shows higher prevalence in middle-aged and older cohorts (40-70 years), reflecting cumulative disease progression over time.
• Despite treatment availability, there remains a significant unmet need, as current therapies do not address the underlying genetic cause or halt disease progression.

Market Overview

• The Stargardt disease market is currently small and largely supportive-care driven, with total market size estimated at $46.7M in 2025, projected to decline slightly in legacy segments but expand overall with pipeline entry.
• Supportive therapies dominate early years, contributing $46-47M annually (2025-2028), but decline to $25M by 2035 as novel therapies gain share.
• Pipeline therapies collectively generate substantial revenue post-2030, with:
• AAVB-039 emerging as a dominant contributor (~$1.5Bn by 2035)
• OCU410ST reaching $320M by 2035
• ALK-001 and Emixustat also showing steady uptake
• The total market transitions from a low-value, fragmented landscape to a high-growth, innovation-driven market, with gene and cell therapies driving exponential value expansion.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

• Sanofi
• Alkeus Pharmaceuticals, Inc.
• AAVantgarde Bio Srl
• Ray Therapeutics, Inc.
• Ocugen
• Splice Bio
• Heronova Pharmaceuticals
• Belite Bio, Inc
• Ascidian Therapeutics, Inc
• VeonGen Therapeutics GmbH
• Astellas Pharma Global Development, Inc.